Skip to main content
Smart Investors Daily
EN

NASDAQ · ENTX

Entera Bio Ltd.

Healthcare · Biotechnology

$3.31

Up+$0.03 (+0.76%)

Updated Nov 22, 2026, 12:07 AM

SID Score

5.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
101.79M
P/E ratio
-41.77
Dividend yield
0.00%
52-week range
$0.91 – $4.20
Volume
469.13K
Avg. volume
154.41K

Price performance · ENTX

ENTX price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 20, 2026

ENTX closed at $3.31 after 20 trading sessions, up 15.56% for the selected period.

Last close
$3.31
Period change
+15.56%
Period low
$2.86
Period high
$3.31
Daily close
View OHLC price history
ENTX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 20, 2026$3.25$3.33$3.175$3.305469.13K
Nov 19, 2026$3.30$3.30$3.18$3.28230.01K
Nov 18, 2026$3.03$3.27$3.00$3.26493.48K
Nov 17, 2026$3.05$3.10$3.00$3.00187.39K
Nov 16, 2026$3.11$3.1165$3.00$3.02208.61K
Nov 13, 2026$3.22$3.265$3.08$3.11155.35K
Nov 12, 2026$3.20$3.24$3.13$3.22170.48K
Nov 11, 2026$3.275$3.275$3.13$3.22103.43K
Nov 10, 2026$3.25$3.25$3.17$3.2498.55K
Nov 9, 2026$3.17$3.4877$3.1101$3.25512.16K
Nov 6, 2026$3.03$3.18$2.91$3.14118.33K
Nov 5, 2026$3.07$3.10$2.90$2.99219.76K
Nov 4, 2026$3.05$3.20$3.05$3.11291.24K
Nov 3, 2026$3.06$3.12$2.99$3.05136.93K
Nov 2, 2026$3.19$3.29$2.99$3.09329.88K
Oct 30, 2026$3.06$3.24$2.95$3.20292.68K
Oct 29, 2026$3.08$3.189$3.01$3.12140.95K
Oct 28, 2026$3.05$3.195$3.005$3.10181.56K
Oct 27, 2026$2.85$3.13$2.81$3.06203.53K
Oct 26, 2026$2.90$2.90$2.80$2.86232.47K

Latest ENTX news

The latest Smart Investors Daily articles mentioning ENTX.

ENTX research

Overview

Company profile and research snapshot.

Company profile

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
ENTX recent ratings
DateFirmRatingTarget
Sep 25, 2026GuggenheimBuy—
Sep 22, 2026Cantor FitzgeraldOverweight—
Sep 18, 2026Leerink PartnersOutperform—
Apr 27, 2026HC Wainwright & Co.Buy—
Feb 9, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 6, 2026

Entera Announces Third Quarter 2026 Financial Results and Business Updates

Clinical Preparations Advanced for EB613 Phase 3 Osteoporosis Study, with First Site Activation Expected in Late 2026 Clinical and Commercial Leadership Expanded with Appointment of Senior Executives and Directors EB613 Enhanced Anabolic Effect Highlighted at ASBMR Plenary Poster Presentation IND-Enabling Activities Ongoing for EB612, in Development with OPKO for Hypoparathyroidism Tel Aviv, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in

Benzinga · Nov 6, 2026

Entera Bio Q3 EPS $(0.11) Misses $(0.07) Estimate

Entera Bio (NASDAQ:ENTX) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.07) by 57.14 percent. This is a 57.14 percent decrease over losses of $(0.07) per share from the

Yahoo · Oct 13, 2026

Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting

Post-hoc Phase 2 data show greater bone mineral density (BMD) gains and anabolic effect with EB613 in postmenopausal women with baseline T-scores of ≤-2.5 (osteoporosis) versus T-scores of >-2.5 (osteopenia) These findings support the potential benefit of EB613 in postmenopausal women with osteoporosis at high risk for fracture - consistent with the study population to be enrolled in Entera’s Phase 3 study TEL AVIV, Israel, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Enter

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.